The life sciences group said manufacturing revenues had grown 60%, with chemistry up by 15%. As previously reported, the drag on performance was the biology operation. However the current year should see this situation reversed.
There was a marked split between halves, with sales up 49% in the second six months compared with the first. Abzena said it had been encouraged by the second-half performance.
It is targeting top-line growth in 2019 at a “slightly higher rate” than 2018, with the performance expected to be second-half weighted.
As at the year-end the company had cash of £6.8mln.